Avadel Pharmaceuticals Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Avadel Pharmaceuticals de 64.2% y 29% por año respectivamente. Se prevé que el BPA crezca en un 64.6% al año. Se espera que la rentabilidad financiera sea de 139.1% en 3 años.

Información clave

64.2%

Tasa de crecimiento de los beneficios

64.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.8%
Tasa de crecimiento de los ingresos	29.0%
Rentabilidad financiera futura	139.1%
Cobertura de analistas	Good
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:AVDL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	392	129	91	127	6
12/31/2025	293	48	32	42	8
12/31/2024	172	-48	20	-32	7
9/30/2024	138	-73	-83	-83	N/A
6/30/2024	95	-106	-114	-114	N/A
3/31/2024	55	-157	-128	-128	N/A
12/31/2023	28	-160	-129	-129	N/A
9/30/2023	9	-159	-116	-116	N/A
6/30/2023	1	-143	-85	-84	N/A
3/31/2023	N/A	-142	-67	-66	N/A
12/31/2022	N/A	-137	-71	-70	N/A
9/30/2022	N/A	-132	-78	-77	N/A
6/30/2022	N/A	-134	-92	-92	N/A
3/31/2022	N/A	-90	-88	-88	N/A
12/31/2021	N/A	-77	-77	-77	N/A
9/30/2021	N/A	-66	-74	-74	N/A
6/30/2021	N/A	-56	-63	-63	N/A
3/31/2021	10	-6	-61	-61	N/A
12/31/2020	22	7	-49	-49	N/A
9/30/2020	33	16	-38	-38	N/A
6/30/2020	48	18	-35	-35	N/A
3/31/2020	55	-21	-29	-29	N/A
12/31/2019	59	-33	-38	-38	N/A
9/30/2019	69	-94	-55	-55	N/A
6/30/2019	75	-101	-68	-67	N/A
3/31/2019	86	-96	-106	-86	N/A
12/31/2018	103	-95	-103	-83	N/A
9/30/2018	117	-40	-93	-72	N/A
6/30/2018	137	-2	N/A	-55	N/A
3/31/2018	154	30	N/A	-27	N/A
12/31/2017	173	68	N/A	17	N/A
9/30/2017	182	81	N/A	38	N/A
6/30/2017	174	40	N/A	37	N/A
3/31/2017	167	-9	N/A	24	N/A
12/31/2016	150	-41	N/A	19	N/A
9/30/2016	152	28	N/A	38	N/A
6/30/2016	167	19	N/A	61	N/A
3/31/2016	177	23	N/A	79	N/A
12/31/2015	173	42	N/A	84	N/A
9/30/2015	127	-64	N/A	52	N/A
6/30/2015	87	-46	N/A	36	N/A
3/31/2015	43	-49	N/A	17	N/A
12/31/2014	15	-89	N/A	-11	N/A
9/30/2014	4	-56	N/A	-11	N/A
6/30/2014	2	-52	N/A	-15	N/A
3/31/2014	4	-65	N/A	-15	N/A
12/31/2013	4	-47	N/A	-21	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AVDL sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que AVDL sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que AVDL sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (29% al año) de AVDL crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (29% al año) de AVDL crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de AVDL sea muy elevada dentro de 3 años (139.1%).

Avadel Pharmaceuticals Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 8.0% to US$22.90

Consensus revenue estimates increase by 18%, EPS downgraded

Consensus EPS estimates fall by 54%, revenue upgraded

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Price target increased by 9.8% to US$18.06

Recent updates

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension (CIII)

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel Pharmaceuticals plc Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

Avadel Pharmaceuticals plc to Report Q2, 2024 Results on Aug 08, 2024

Avadel Pharmaceuticals plc Announces First Patient Dosed in Phase 3 REVITALYZ Trial of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals: Inflection Point Ahead

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension (CIII) Data at Sleep 2024

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals plc has completed a Follow-on Equity Offering.

Avadel Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Avadel Pharmaceuticals plc to Report Q1, 2024 Results on May 08, 2024

New major risk - Share price stability

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Price target increased by 8.0% to US$22.90

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%, EPS downgraded

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

New minor risk - Insider selling

Consensus EPS estimates fall by 54%, revenue upgraded

Key Executive recently bought US$188k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Avadel Pharmaceuticals plc Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-At-Bedtime Oxybate Dosing for Narcolepsy

Price target increased by 9.8% to US$18.06

Avadel Pharmaceuticals plc Announces U.S. Commercial Launch of LUMRYZ for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Avadel Pharmaceuticals plc Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Independent Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 17%

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Price target increased by 20% to US$15.85

Consensus revenue estimates fall by 15%

Consensus revenue estimates increase by 15%, EPS downgraded

Avadel Pharmaceuticals plc Announces Publication of Real-World Data Describing Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybate

Insufficient new directors

Price target increased to US$12.25

Independent Director recently bought US$156k worth of stock

Avadel Pharmaceuticals Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Price target increased to US$10.95

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Price target increased to US$10.10

Avadel Pharmaceuticals plc Announces Tentative Approval of LUMRYZ Extended-Release Oral Suspension

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel Pharmaceuticals Provides Corporate Update

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Senior VP & CFO recently bought US$107k worth of stock

Price target decreased to US$11.30

Consensus revenue estimates fall by 15%

Avadel Pharmaceuticals plc to Report Q1, 2022 Results on May 09, 2022

Avadel Pharmaceuticals plc, Annual General Meeting, Aug 04, 2022

Consensus revenue estimates fall by 16%